Citations
415
138.3 per year
Published
2022
Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial
The Lancet Global Health•2022
Authors
G Reis, EA dos Santos Moreira-Silva, DCM Silva, L Thabane, G Milagres, AC Ferreira, CQ dos Santos, VEG de Souza Campos, AM Nogueira, APM de Almeida, EDS Callegari, ADF de Figueiredo Neto, JI Forrest, H Ruton, L Sprague, P McKenzie, C Guo, EJ Mills, ...
The Lancet
COVID-19
Fluvoxamine
Abstract
Recent evidence indicates a potential therapeutic role of fluvoxamine for COVID-19. In the TOGETHER trial for acutely symptomatic patients with COVID-19, we aimed to evaluate the effectiveness of fluvoxamine in preventing hospitalisation or extended observation in an emergency setting among high-risk outpatients with early COVID-19 symptoms.
Related Publications
Effect of early treatment with ivermectin among patients with Covid-19
New England Journal of Medicine • 2022
COVID-19
Ivermectin
Interventions to improve adherence to antiretroviral therapy: a systematic review and network meta-analysis
The Lancet HIV • 2017
The Lancet
HIV/AIDS
A real-time dashboard of clinical trials for COVID-19
The Lancet Digital Health • 2020
The Lancet
COVID-19